FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Tecfidera (BG00012) or Standard of Care













The primary objective of this study is to determine whether BG00012 (dimethyl fumarate, DMF, Tecfideraâ„¢) taken over 12 months is effective in reducing Multiple Sclerosis-related fatigue, as measured by changes in the Fatigue Scale for Motor and Cognitive Functions (FSMC), in participants with relapsing remitting multiple sclerosis (RRMS). The secondary objectives of this study are as follows: To describe variation from baseline in fatigue scores effects on motor and cognitive function or Fatigue Scale for Motor and Cognitive Functions (FSMC) and fatigue severity (Fatigue Severity Scale [FSS]) at 1, 3, and 6 months in participants receiving standard of care (SOC) treatment; To investigate changes from baseline in fatigue effects on motor and cognitive function (FSMC) and fatigue severity (Fatigue Severity Scale [FSS]) at 1, 3, 6, 9, and 12 months in participants receiving BG00012; To assess the impact of BG00012 on patient-reported outcomes (PROs), including work productivity (Work Productivity and Activity Impairment-Multiple Sclerosis questionnaire [WPAI-MS]), health-related quality of life (Short Form Health Survey [SF-12] or the 15-dimensional health-related quality of life [15D HRQoL] questionnaire), depression (Beck Depression Inventory-Fast Screen [BDI-FS]), and sleepiness (Epworth Sleepiness Scale [ESS]) at 6 and 12 months in participants receiving BG00012; To examine whether an association exists between fatigue and baseline demographics and disease characteristics (e.g., age, sex, disease duration, baseline disease activity, treatment history, expanded disability status scale [EDSS] score, and PROs); and To assess any changes in fatigue-related medication use.


Story Source: The above story is based on materials provided by CLINICALTRIALS
Note: Materials may be edited for content and length
Click here to read more

Labels: ,



Go to Newer News Go to Older News